Helex is extending the frontier of breakthrough gene editing-based therapeutics to meet the significant underserved medical needs of patients with genetic kidney diseases.
Helex is extending the frontier of breakthrough gene editing-based therapeutics to meet the significant underserved medical needs of patients with genetic kidney diseases.
Taking the promise of gene editing and non-viral targeted delivery to the kidney
Mission to develop therapies for over 800 million people worldwide suffering from chronic kidney diseases, starting with Autosomal Dominant Polycystic Kidney Disease
Leveraging our proprietary drug design and lipid nanoparticle delivery platforms to develop a robust renal franchise
Reshaping gene editing by leveraging nature’s own operating system-epigenome and the 3-D spatial organization of the genome to develop effective, safe and reliable therapies to provide cures to genetic conditions.
Platform enables target cell & tissue specific editing for high specifity
Technology applicable across all targets and tissues types
Bioinformatics to assess edit impact on genome, epigenome & long-term safety